ANTIBODIES TO ETANERCEPT AND ADALIMUMAB IN RHEUMATOID ARTHRITIS INADEQUATE RESPONDERS AND CLINICAL OUTCOMES AFTER AN ACTIVE SWITCH TO INFLIXIMAB

被引：0
|
作者：
Pool, C. [1 ]
Shankar, G. [2 ]
Schantz, A. [2 ]
Gunn, G. [2 ]
Bolce, R. [1 ]
Leirisalo-Repo, M. [3 ]
Wang, J. [2 ]
Goldman, J.
DeHoratius, R. [1 ]
Fleischmann, R. [4 ]
Decktor, D. [1 ]
机构：
[1] Janssen Serv LLC, Horsham, PA USA
[2] Janssen R&D LLC, Spring House, PA USA
[3] Helsinki U Cent Hosp, Helsinki, Finland
[4] Metroplex Clin Res Ctr, Dallas, TX USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：224 / 225
页数：2
相关论文
共 50 条
  • [41] Infliximab, etanercept and leflunomide in rheumatoid arthritis. Clinical experience in southern Sweden
    Crnkic, Meliha
    Petersson, Ingemar F.
    Saxne, Tore
    Geborek, Pierre
    RHEUMATOLOGY, 2001, 40 : 82 - 82
  • [42] Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab
    Matsuno, Hiroaki
    MODERN RHEUMATOLOGY, 2010, 20 (06) : 561 - 565
  • [43] INCIDENCE OF ANTI-DRUG ANTIBODIES IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM ARGENTINA TREATED WITH ADALIMUMAB, ETANERCEPT, OR INFLIXIMAB IN A REAL-WORLD SETTING
    Maid, Pablo
    Real, Rosa
    Pedersen, Ron
    Shen, Qi
    Hidalgo, Rodolfo
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 131 - 131
  • [44] Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy
    Comby, E
    Tanaff, P
    Mariotte, D
    Costentin-Pignol, V
    Marcelli, C
    Ballet, JJ
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (01) : 24 - 30
  • [45] Outcomes in Patients with Rheumatoid Arthritis Initiating Therapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
    Pappas, Dimitrios
    O'Brien, Jacqueline
    Guo, Lin
    Shan, Ying
    Baker, Joshua
    Kricorian, Gregory
    Stryker, Scott
    Collier, David
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 856 - 857
  • [46] Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
    Pappas, Dimitrios
    O'Brien, Jacqueline
    Kelleman, Mike
    Guo, Lin
    Shan, Ying
    Baker, Joshua
    Kricorian, Greg
    Stryker, Scott
    Collier, David
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2798 - 2800
  • [47] OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING THERAPY WITH ETANERCEPT, ADALIMUMAB, OR JANUS KINASE INHIBITORS
    Pappas, D. A.
    O'brien, J.
    Guo, L.
    Shan, Y.
    Baker, J.
    Kricorian, G.
    Stryker, S.
    Collier, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 529 - 530
  • [48] LONG-TERM CLINICAL EFFECTIVENESS OF ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB IN RHEUMATOID ARTHRITIS (RA): AN OBSERVATIONAL STUDY FROM ITALIAN REGISTER, GISEA
    Iannone, F.
    Marchesoni, A.
    Sarzi-Puttini, P.
    Gorla, R.
    Govoni, M.
    Carletto, A.
    Ferraccioli, G.
    Ferri, C.
    Punzi, L.
    Salaffi, F.
    Foti, R.
    Lapadula, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 932 - 932
  • [49] DOES CONCENTRATION OF ANTIBODIES TO ETANERCEPT AND ADALIMUMAB CORRELATES WITH PARAMETERS OF DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS?
    Nedovic, J.
    Stamenkovic, B.
    Stojanovic, S.
    Zivkovic, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1009 - 1010
  • [50] RETENTION RATES OF ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB AS BIOTHERAPIES FOR RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, OR PSORIATIC ARTHRITIS PATIENTS IN DAILY PRACTICE IN AUVERGNE (FRANCE)
    Soubrier, M.
    Fan, A.
    Couderc, M.
    Malochet-Guinamand, S.
    Mathieu, S.
    Giraud, C.
    Tournadre, A.
    Dubost, J. -J.
    Pereira, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1756 - 1756
12345